Huons & KRICT’s co-development agreement of targeted liver disease therapy

Published: 2018-06-20 16:30:05

Updated: 2018-06-20 16:30:05

Huons(CEO Ki-Ahn Um) will take joint development of a new drug for liver diseases with the Korea Research Institute of Chemical Technology.

Huons and the Korea Research Institute of Chemical Technology(KRICT) announced a co-development of a new drug for liver diseases using the ‘Proteolysis-Targeting Chimaera’ at the KRICT building on the 14^thbetween Huons CEO Ki-An Um and KRICT Chairman Sung...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.